The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia
This is a prospective multi-center study to investigate efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) combined with azacitidine and B-cell lymphoma-2 (Bcl-2) inhibitor in patients with myeloid blast phase chronic myeloid leukemia (CML-MBP).
• age ≥ 18 years old;
• philadelphia chromosome (Ph)-positive or BCR::ABL-positive;
• serum creatinine ≤ 1.5 × upper limit of normal (ULN) or 24h creatinine clearance ≥ 50 mL/min when serum creatinine was \> 1.5 × ULN;
• serum total bilirubin ≤ 1.5 × ULN;
• aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × ULN;
• amylase ≤ 1.5 × ULN; (7) lipase ≤ 1.5 × ULN;
• ejection fraction \> 50%; corrected QT interval on electrocardiographic evaluation was ≤ 450 ms in men or ≤ 470 ms in women.